BeOne Medicines has reached a voluntary agreement with the US government covering cancer medicine access, future pricing and continued investment in US pharmaceutical manufacturing.

Interpharma says seven of 22 innovative medicines introduced between January 2025 and June 2026 were not submitted for Swiss reimbursement, as companies consider the potential implications of Swiss prices for the US market.